Lynn Seely Lyell Immunopharma, Inc. (LYEL) insider trading activity

Lynn Seely is President and CEO of Lyell Immunopharma, Inc.. Currently has a direct ownership of 67,159 shares of LYEL, which is worth approximately $1.14 Million. The most recent transaction as insider was on Nov 10, 2025, when has been sold 412 shares (Common Stock) at a price of $16.11 per share, resulting in proceeds of $6,637. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 67.2K

0.61% 3M change

66.42% 12M change

Total Value Held $1.14 Million

Lynn Seely Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 10 2025	SELL Open market or private sale	$6,637 $16.11 p/Share	412 Reduced 0.61%	67,159 Common Stock
Aug 21 2025	SELL Open market or private sale	$76,488 $10.54 p/Share	7,257 Reduced 9.7%	67,571 Common Stock
Aug 20 2025	BUY Grant, award, or other acquisition	-	40,000 Added 34.83%	74,828 Common Stock
Aug 12 2025	SELL Open market or private sale	$4,198 $10.34 p/Share	406 Reduced 1.15%	34,828 Common Stock
Aug 11 2025	SELL Open market or private sale	$4,117 $10.53 p/Share	391 Reduced 1.1%	35,234 Common Stock
Mar 14 2025	BUY Open market or private purchase	$106,750 $0.61 p/Share	175,000 Added 19.72%	712,500 Common Stock
Feb 10 2025	BUY Grant, award, or other acquisition	-	337,500 Added 38.57%	537,500 Common Stock

Feb 09 2024	BUY Grant, award, or other acquisition	-	200,000 Added 50.0%	200,000 Common Stock

Also insider at

BPMC

Blueprint Medicines Corp Healthcare

Director

Lynn Seely

President and CEO

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells LYEL shares.

Notify only if

Value

Insider Trading

Get notified when an Lyell Immunopharma, Inc. insider buys or sells LYEL shares.

Notify only if

Operation

Value

Type

News

Receive news related to Lyell Immunopharma, Inc.

Track Activities on LYEL

Account